Enesi Pharma Signs a Cooperative R&D Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for Shigella’s vaccine development

 Enesi Pharma Signs a Cooperative R&D Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for Shigella’s vaccine development

Enesi Pharma Signs a Cooperative R&D Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR) for Shigella’s vaccine development

Shots:

  • The agreement is focused on development of needle-free and solid-dose formulation for Shigella flexneri 2a artificial Invaplex (Sfl2a InvaplexAR) vaccine using Enesi Pharma’s ImplaVax technology
  • WRAIR will examine biochemical integrity and immunogenicity of the solid-dose product in Shigella disease models
  • Shigella infection (shigellosis) is a communicable form of bacterial diarrheal disease and is responsible for ~165M cases/year of severe dysentery. It is a priority for the US Army and for vaccine developers targeting pediatric populations

Click here to read full press release/ article | Ref: Enesi Pharma | Image:  Enesi Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post